NCT03398694
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Must be an SRS candidate per radiation oncologist
Exclusions: Patients with more than 4 brain metastases or any lesion over 5 cm; Patients with leptomeningeal metastases; Prior WBRT
https://ClinicalTrials.gov/show/NCT03398694